Catégorie : Cannabis therapeutique

Beta-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain, Esraa Aly et al.,

Beta-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain Esraa Aly, Maitham A. Khajah and Willias Masocha Molecules, 2020, 25, 106; doi:10.3390/molecules25010106   Abstract : Neuropathic pain associated with nucleoside reverse transcriptase inhibitors (NRTIs), therapeutic agents for human immunodeficiency virus (HIV), responds poorly to available drugs. Smoked cannabis was reported to relieve HIV-associated neuropathic pain in clinical trials. Some constituents of cannabis (Cannabis sativa) activate cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors. However, activation of the CB1 receptor is associated with side eects such as psychosis and physical dependence. Therefore, we investigated the effect of B-caryophyllene (BCP), [...]

Lire la suite

As CBD Oil Flirts with Mainstream, Questions Mount, Kathleen Doheny, Medscape, 2018

As CBD Oil Flirts with Mainstream, Questions Mount Kathleen Doheny Medscape, June 11, 2018 Anxiety is a given for Jessica Singer, 25, who juggles her job at a marijuana dispensary with her night-time gigs as a stand-up comedian in Los Angeles. So when it’s time for bed, "I can't turn off my brain,'' she says. Now she does, with the help of a new bedtime ritual -- a ''snack" of two gummy bears containing CBD. CBD, or cannabidiol, is a substance from marijuana that lacks the ''high'' of the THC (tetrahydro-cannabinol) also found in marijuana. The remedy is affordable for her -- about $35 [...]

Lire la suite

A Physician’s Guide to the Cannabidiol Craze, Angela Coombs & Diana M. Martinez, 2013

COMMENTARY A Physician's Guide to the Cannabidiol Craze Angela Coombs, MD; Diana M. Martinez, MD Medscape, May 31, 2019 Last month at the Columbia University Department of Psychiatry in upper Manhattan, Columbia chief psychiatry resident Dr Angela Coombs interviewed addiction expert Dr Diana Martinez on a number of issues related to the rising popularity and usage of cannabidiol (CBD). This transcript has been edited for clarity.   Angela Coombs, MD: Hi. My name is Dr Angela Coombs and I'm a chief resident here at Columbia. We are so happy to be able to have Dr Diana Martinez, who's a professor in psychiatry at Columbia and an expert [...]

Lire la suite

‘Standard THC units’: a proposal to standardize dose across all cannabis products and methods of administration, T.P. Freeman & V.Lorenzetti, 2019

'Standard THC units': a proposal to standardize dose across all cannabis products and methods of administration T.P. Freeman, V.Lorenzetti Addictions, 2019, Oct 12. doi : 10.1111/add.14842 © 2019 Society for the Study of Addiction. Abstract BACKGROUND AND AIMS : Cannabis products are becoming increasingly diverse, and vary considerably in concentrations of ∆9 -tetrahydrocannabinol (THC) and cannabidiol (CBD). Higher doses of THC can increase the risk of harm from cannabis, while CBD may partially offset some of these effects. Lower Risk Cannabis Use Guidelines currently lack recommendations based on quantity of use, and could be improved by implementing standard units. However, there is currently no consensus on [...]

Lire la suite

Bibliographie CANNABINOÏDES et Traitement des Nausées et Vomissements, Docteur Christian SUEUR, GRECC, 2e édition, janvier 2020

Bibliographie CANNABINOÏDES et Traitement des Nausées et Vomissements   Docteur Christian SUEUR, GRECC, 2e édition, janvier 2020.   Le Cannabis comme anti-émétique :   Les prescriptions médicales, chez les adultes (THC naturel ou synthétique - Nabilone) comme chez les enfants (delta 8-THC, Abrahamov et al, 1995), ont débutées dès 1975. L’efficacité a été prouvée dans de nombreux essais cliniques, et de nombreuses méta-analyses (8/9 pour le cannabis et 3/3 pour le Nabilone, Penta et al, 1981). Par contre les effets psychotropiques peuvent être mal supportés par de nombreux patients, et justifie l’arrêt, ou la diminution des doses. Les associations variables THC/CBD présente un intérêt probable. Aucun effet indésirable persistant ou fatal [...]

Lire la suite

Cannabis in Cancer Care, D.I. Abrams and M. Guzman, 2015

Cannabis in Cancer Care D.I. Abrams and M. Guzman Clinical Pharmacology & Therapeutics, 2015, 97, (6), 575-586. Doi : 10.1002/cpt.108   Cannabis has been used inmedicine for thousands of years prior to achieving its current illicit substance status. Cannabinoids, the active components of Cannabis sativa,mimic the effects of the endogenous cannabinoids (endocannabinoids), activating specific cannabinoid receptors, particularly CB1 found predominantly in the central nervous system and CB2 found predominantly in cells involved with immune function. Delta-9-tetrahydrocannabinol, themain bioactive cannabinoid in the plant, has been available as a prescriptionmedication approved for treatment of cancer chemotherapy-induced nausea and vomiting and anorexia associated with the AIDS wasting syndrome. Cannabinoidsmay [...]

Lire la suite

Are Your Patients Taking CBD? – Medscape – January 15, 2020

Are Your Patients Taking CBD? - Medscape - January 15, 2020 https://www.medscape.com/viewarticle/923801   Cannabidiol (CBD) is having its moment in the sun. A Gallup poll from last August found that 1 in 7 Americans use CBD, that 11% of users are 50 to 64 years of age, and that 8% are at least 65 years of age. Pain relief, anxiety, insomnia, and arthritis are the top reasons for use. Nearly 4 in 10 Americans think CBD oils should be legally available for adults to buy over the counter. Although the 2018 Farm Bill removed hemp (cannabis and cannabis derivatives such as CBD that contain less than 0.3% THC) [...]

Lire la suite

Cannabinoid Regulation of Fear and Anxiety : an Update, Eleni P. Papagianni & Carl W. Stevenson, 2019

Cannabinoid Regulation of Fear and Anxiety : an Update Eleni P. Papagianni & Carl W. Stevenson Current Psychiatry Reports, 2019, 21, 38 doi : 10.1007/s11920-019-1026-z   Abstract Purpose of Review : Anxiety- and trauma-related disorders are prevalent and debilitating mental illnesses associated with a significant socioeconomic burden. Current treatment approaches often have inadequate therapeutic responses, leading to symptom relapse. Here we review recent preclinical and clinical findings on the potential of cannabinoids as novel therapeutics for regulating fear and anxiety. Recent Findings : Evidence from preclinical studies has shown that the non-psychotropic phyto-cannabinoid cannabidiol and the endocannabinoid anandamide have acute anxiolytic effects and also regulate learned fear [...]

Lire la suite

Regulation of nausea and vomiting by cannabinoids, Linda A Parker et al., 2011

Regulation of nausea and vomiting by cannabinoids Linda A Parker, Erin M Rock and Cheryl L Limebeer British Journal of Pharmacology, 2011, 163, 1411-1422. Doi : 10.1111/j.1476-5381.2010.01176.x   Abstract Considerable evidence demonstrates that manipulation of the endocannabinoid system regulates nausea and vomiting in humans and other animals. The anti-emetic effect of cannabinoids has been shown across a wide variety of animals that are capable of vomiting in response to a toxic challenge. CB1 agonism suppresses vomiting, which is reversed by CB1 antagonism, and CB1 inverse agonism promotes vomiting. Recently, evidence from animal experiments suggests that cannabinoids may be especially useful in treating the more difficult to control [...]

Lire la suite